At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABSI Absci Corporation.
Market Closed 12-20 16:00:00 EST
2.99
+0.07
+2.40%
盘后3.11
+0.12+4.11%
19:59 EST
High3.09
Low2.86
Vol2.50M
Open2.88
D1 Closing2.92
Amplitude7.71%
Mkt Cap343.42M
Tradable Cap257.88M
Total Shares114.86M
T/O7.49M
T/O Rate2.90%
Tradable Shares86.25M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Absci Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.